share_log

Multiple Surgeon Presentations to Highlight RxSight Light Adjustable Lens System at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting

Multiple Surgeon Presentations to Highlight RxSight Light Adjustable Lens System at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting

在即將舉行的美國白內障和屈光手術學會年會上,多位外科醫生髮表演講,重點介紹 rxSight 可調光鏡片系統
GlobeNewswire ·  2023/04/25 04:11

ALISO VIEJO, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that its Light Adjustable Lens system will be the subject of multiple surgeon presentations at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) being held at the San Diego Convention Center on May 5-8, 2023.

加利福尼亞州阿里索維耶霍,2023 年 4 月 24 日(GLOBE NEWSWIRE)— (納斯達克股票代碼:RXST)— RxSight, Inc. 是一家致力於爲白內障手術患者提供高質量定製視覺的眼科醫療器械公司,今天宣佈,其可調光鏡頭系統將成爲2023年5月5日至8日在聖地亞哥會議中心舉行的美國白內障和屈光手術學會(ASCRS)年會上多位外科醫生演講的主題。

Key papers and presentations include:

主要論文和演講包括:

Friday, May 5
LAL for Patients Who Desire Presbyopia Correction
Neda Shamie, MD, ABO (1:10 p.m., SDCC, Upper Level, Room 6A)

5月5日,星期五
LAL 適用於希望矯正老花眼的患者
Neda Shamie,醫學博士,ABO(下午 1:10,SDCC,上層,6A 室)

Saturday, May 6
Integrating Small Aperture Technology and Light Adjustable Lenses to Broaden the Patients Able to Attain Decreased Spectacle Dependence
Cathleen M. McCabe, MD (3:35 p.m., Upper Level, Room 20D)

5 月 6 日,星期六
整合小孔徑技術和光度可調鏡片,擴大患者對眼鏡依賴的減少能力
醫學博士 Cathleen M. McCabe(下午 3:35,上層,20D 房間)

LAL Customized Monovision Will Minimize the Disparity
Nicole R. Fram, MD, ABO (4:23 p.m., SDCC, Upper Level, Room 20D)

LAL 定製單視鏡將最大限度地減少差異
Nicole R. Fram,醫學博士,ABO(下午 4:23,SDCC,上層,20D 房間)

Sunday, May 7
Refractive Outcomes of Patients with Corneal Astigmatism after Implantation with a Light Adjustable Lens, Toric Lens, or Monofocal Lens
Francesca Kahale, MD; Wassef Chanbour, MD; Jason E. Brenner, MD; Samir A. Melki, MD, PhD (9:20 a.m., SDCC, Upper Level, Room 1B)

5 月 7 日,星期日
角膜散光患者植入光度可調透鏡、復曲面透鏡或單焦透鏡後的屈光預後
Francesca Kahale,醫學博士;Wassef Chanbour,醫學博士;Jason E. Brenner,醫學博士;Samir A. Melki,醫學博士(上午 9:20,SDCC,Upper Level,1B 室)

A Retrospective Single-Practice, Single-Surgeon, Multi-Provider Study on the Performance of the Second-Generation Light Adjustable Lens
Avery Zhou, BA, MA; Eva I. Liang, MD, FASC, ABO (1 :35 p.m., SDCC, Upper Level, Room 3)

關於第二代可調光鏡片性能的回顧性單一診所、單外科醫生、多提供者研究
Avery Zhou,文學學士,MA;Eva I. Liang,醫學博士,FASC,ABO(下午 1:35,SDCC,上層,3 號房間)

Light Adjustable Intraocular Lens and the Effects of Postoperative Astigmatism on Near Vision
Cory J. Pickett, MSN, FNP-C, COA, CRNO; Sloan W. Rush, MD, ABO; Jason C. Smith, PA (1:40 p.m., SDCC, Upper Level, Room 3)

光線可調人工晶狀體與術後散光對近視的影響
Cory J. Pickett,MSN,FNP-C,COA,CRNO;Sloan W. Rush,醫學博士,ABO;Jason C. Smith,賓夕法尼亞州(下午 1:40,SDCC,Upper Level,3 號房間)

Increased Depth of Focus with the Light Adjustable Intraocular Lens
Cory J. Pickett, MSN, FNP-C, COA, CRNO; Sloan W. Rush, MD, ABO; Jason C. Smith, PA (1:45 p.m., SDCC, Upper Level, Room 3)

使用可調光度的人工晶體增加對焦深度
Cory J. Pickett,MSN,FNP-C,COA,CRNO;Sloan W. Rush,醫學博士,ABO;Jason C. Smith,賓夕法尼亞州(下午 1:45,SDCC,Upper Level,3 號房間)

Refractive and Visual Outcomes in Light Adjustable Lens Surgery Using Fully Automated Manifest Refraction
Andrea Rivas, MD; Erik A. Navas Villar, MD; Nora E. Robledo, OD; Arturo S. Chayet, MD; Maximiliano Barrera-Sanchez, MD; Ivone Curiel Arce, MD; Arie Maya, MD, MHA (1:57 p.m., SDCC, Upper Level, Room 3)

使用全自動明顯折射進行可調光鏡手術的屈光和視覺結果
安德里亞·裏瓦斯,醫學博士;埃裏克·納瓦斯·維拉爾,醫學博士;Nora E. Robledo,OD;Arturo S. Chayet,醫學博士;醫學博士馬克西米利亞諾·巴雷拉-桑切斯;醫學博士 Arie Maya,MHA(下午 1:57,SDCC,Upper Level,3 號房間)

Clinical Outcomes of a Light Adjustable Lens in Eyes with Prior Corneal Refractive Surgery
Adam Bleeker, MD; Marlee E. Jones, BSc; Tanner J. Ferguson, MD; Daniel Terveen, MD; John P. Berdahl, MD; Brent A. Kramer, MD; Vance M. Thompson, MD (2:29 p.m., SDCC, Upper Level, Room 3)

既往角膜屈光手術的眼部可調光鏡的臨床結果
亞當·布萊克,醫學博士;Marlee E. Jones,理學學士;Tanner J. Ferguson,醫學博士;Daniel Terveen,醫學博士;John P. Berdahl,醫學博士;Brent A. Kramer,醫學博士(下午 2:29,SDCC,Upper Level,3 號房間)

Multi-Center Study: Visual Outcomes in 143 Patients Bilaterally Implanted with the Post-Op Customizable Light Adjustable Lens (LAL)
John A. Vukich, MD (4:40 p.m., SDCC, Upper Level, Room 1B)

多中心研究:143 名雙向植入術後可定製光度可調鏡頭 (LAL) 的患者的視覺結果
醫學博士 John A. Vukich(下午 4:40,SDCC,上層,1B 室)

Optimizing Vision at All Distances with the Light Adjustable Lens (LAL)
T. Hunter Newsom, MD, ABO; Brian Szabo, DO (4:45 p.m., SDCC, Upper Level, Room 1B)

使用光度可調鏡頭 (LAL) 優化所有距離的視力
T. Hunter Newsom,醫學博士,ABO;Brian Szabo,DO(下午 4:45,SDCC,上層,1B 室)

In addition, numerous surgeons will present their LAL experience at the RxSight booth in the convention exhibit hall (Booth #1911). A schedule of these presentations, which are not affiliated with the official ASCRS program, is available at and at the company's booth throughout ASCRS.

此外,許多外科醫生將在會議展覽廳(展位 #1911)的 RxSight 展位上展示他們的 LAL 經驗。這些演講的時間表與ASCRS官方計劃無關,可在整個ASCRS的公司展位上查閱。

About RxSight, Inc.
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery enabling doctors to customize and deliver high-quality of vision to patients after cataract surgery. Additional information about RxSight can be found at .

關於 rxSight, Inc.
RxSight, Inc. 是一家商業階段的醫療技術公司,致力於改善白內障手術後患者的視力。rxSight 光線可調鏡頭系統由 rxSight 光線可調鏡頭 (LAL)、rxSight 光傳送設備 (LDD) 和配件組成,是首款也是唯一一種可在手術後調整的市售人工晶體 (IOL) 技術,使醫生能夠定製白內障手術後爲患者提供高質量的視力。有關 RxSight 的更多信息,請訪問。

Forward-Looking Statements
This press release contains forward-looking statements. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. Potential risks and uncertainties may also include the continued efficacy and safety profile of our products as might be suggested in presentations at the ASCRS meeting. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

前瞻性陳述
本新聞稿包含前瞻性陳述。此類陳述與未來事件或我們未來的財務業績有關,涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致我們或我們行業的實際業績、活動水平、業績或成就與這些前瞻性陳述所表達、暗示或推斷的任何未來業績、活動水平、業績或成就存在重大差異,還涉及我們維持現金餘額以及成功將我們目前正在開發的候選產品商業化或合作的能力。正如ASCRS會議上的演講所暗示的那樣,潛在的風險和不確定性還可能包括我們產品的持續功效和安全性。在某些情況下,你可以用 “可能”、“將”、“應該”、“可以”、“會”、“期望”、“計劃”、“打算”、“預期”、“預期”、“相信”、“估計”、“預測”、“項目”、“潛力” 或 “繼續” 等術語來識別前瞻性陳述,也可以用這些術語和其他相同術語的否定詞來識別前瞻性陳述。這些陳述僅是基於我們當前對未來事件的預期和預測的預測。您不應過分依賴這些陳述。實際事件或結果可能存在重大差異。在評估這些陳述時,應特別考慮各種因素。這些因素和其他因素可能導致我們的實際業績與任何前瞻性陳述存在重大差異。除非適用法律要求,否則我們沒有義務在本新聞稿發佈之日之後更新任何前瞻性陳述,以使這些陳述符合意想不到的事件的發生。

Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com

公司聯繫人:
Shelley B. Thunen
首席財務官
sthunen@rxsight.com

Investor Relations Contact:
ir@rxsight.com

投資者關係聯繫人:
ir@rxsight.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論